西陇科学股份有限公司 2021 年半年度报告全文 西陇科学股份有限公司 2021 年半年度报告 2021 年 07 月 1 西陇科学股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人黄伟鹏、主管会计工作负责人黄少群及会计机构负责人(会计主 管人员)王庆东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 半年度报告涉及未来计划、发展战略等前瞻性陈述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应该理解 计划、预测和承诺之间的差异。 | --- | |----------------------------------------------------------------------| | | | 1 、敬请投资者认真阅读本报告全文，并注意以下风险因素：宏观经济下行 | | 的风险、安全生产的风险、环保风险，技术研发风险、管理风险等。详见本报 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2020, representing a year-on-year increase of 15%[20]. - The net profit attributable to shareholders was RMB 200 million, which is a 10% increase compared to the previous year[20]. - The company's operating revenue for 2020 was ¥6,243,170,933.20, representing an increase of 87.05% compared to 2019[28]. - The net profit attributable to shareholders for 2020 was ¥56,873,463.11, a growth of 47.62% from the previous year[28]. - The net profit after deducting non-recurring gains and losses reached ¥14,188,964.83, showing a significant increase of 27,107.39% compared to 2019[28]. - The gross margin improved to 35%, up from 30% in the previous year, reflecting better cost management[20]. - The company reported a basic earnings per share of ¥0.10 for 2020, an increase of 42.86% from ¥0.07 in 2019[28]. - The company reported a significant increase in operating costs, which rose by 108.95% to ¥5,584,335,655.13[73]. - The company reported a total operating cost of 5.76 billion CNY under the new standards, compared to 5.70 billion CNY under the old standards[172]. Investment and R&D - The company plans to invest RMB 300 million in R&D for new product development in the upcoming year[20]. - Research and development expenses increased by 17.29% to ¥102,719,157.81, compared to ¥87,580,449.56 in 2019[68]. - The company has been recognized as a "National High-tech Enterprise" and has over 66 independent intellectual property patents, reflecting its strong R&D capabilities[55]. - The company is investing in research and development to strengthen its technical capabilities and respond to market demands effectively[124]. - The company launched new product development initiatives, including semiconductor materials and lithium battery adhesives, enhancing its product service capabilities[63]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 20% market share within three years[20]. - Future guidance estimates a revenue growth of 20% for 2021, driven by new product launches and market expansion[20]. - The company is focusing on industrial upgrades and new project development to maintain market position amid increasing environmental and safety risks in the chemical industry[133]. - The company is committed to developing its core reagent business while expanding into the electronic and health industries[115]. - The company recognizes the rising market potential in the in vitro diagnostic reagent sector, which is entering a growth phase with significant room for development compared to mature markets[119]. Operational Efficiency - The company is actively expanding its production capacity and product range in response to the growing demand for high-purity chemical products in the 5G market[55]. - The company is enhancing its management systems to address the complexities arising from strategic transformations and business expansions[124]. - The company aims to enhance management and data analysis capabilities by optimizing its management structure and operational systems, focusing on improving productivity in marketing and production[116]. - The company is implementing a digital platform, "Tomato CLUB," for internal sales management, enhancing user experience through integrated services[67]. Shareholder Returns and Dividends - The company will not distribute cash dividends or issue bonus shares for the year 2020[7]. - The company reported a net profit attributable to ordinary shareholders of 56,873,463.11 yuan in 2020, with a cash dividend payout ratio of 0.00%[130]. - The company has established a shareholder return plan for 2020-2022, which has been approved by the board and aims to enhance the shareholder return mechanism[129]. - The company has not proposed a cash dividend distribution plan for 2020 despite having positive distributable profits[134]. Risk Management and Compliance - The company faces risks from macroeconomic downturns that could lead to reduced market demand, impacting profits and inventory levels[120]. - Safety production remains a critical concern for the company, which has implemented measures to mitigate risks associated with hazardous materials during production[121]. - The company is actively managing its investment commitments and ensuring compliance with all relevant laws and regulations[164]. - The company has established a risk management framework for its asset management products, ensuring equal rights and risks for all investors[164]. Industry Trends - The IVD market in China is expected to grow at a rate of over 15% due to the ongoing medical reform and the shift towards preventive healthcare[47]. - The electronic chemicals industry is experiencing rapid growth due to the increasing demand from downstream applications such as semiconductors and solar energy, driven by technological advancements[117]. - The overall market concentration in the chemical reagent industry is increasing, with stronger companies rapidly developing to catch up with international leaders[46]. Corporate Structure and Governance - The company is implementing a flat organizational structure to improve management efficiency and support business development[115]. - The company has committed to avoiding competition with its actual controllers and has ongoing commitments related to asset restructuring and refinancing[135]. - The company confirmed that its partners will not accept any financial assistance or guarantees from West Long Chemical[164].

西陇科学股份有限公司 2021 年第一季度报告全文 西陇科学股份有限公司 2021 年第一季度报告 2021 年 04 月 1 西陇科学股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人黄少群及会计机构负责人(会计主 管人员)王庆东声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 | 上年同期 | ...

西陇科学股份有限公司 2020 年第三季度报告 2020 年 10 月 西陇科学股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员均保证季度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人黄少群及会计机构负责人(会计主 管人员)王庆东声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|------------------|-------------------------------| | □ 是 √ 否 | 本报告期末 ...

西陇科学股份有限公司 2020 年半年度报告 2020 年 08 月 西陇科学股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人黄伟鹏、主管会计工作负责人黄少群及会计机构负责人(会计主 管人员)王庆东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第四节"经营情况讨论与分析"的"十、公司面临的风险和应对 措施"中描述了公司经营中可能存在的风险及应对的措施，敬请投资者关注相关 内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 西陇科学股份有限公司 2020 年半年度报告全文 目录 | --- | |-------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2019, representing a year-on-year growth of 15%[16] - The company's operating revenue for 2019 was ¥3,337,661,961.68, a decrease of 0.52% compared to the previous year[24] - The net profit attributable to shareholders was ¥38,527,214.95, representing a significant decline of 45.41% year-over-year[24] - The net profit after deducting non-recurring gains and losses was ¥52,151.14, a drastic drop of 99.71% compared to the previous year[24] - The total operating revenue for 2019 was ¥3,337,661,961.68, a decrease of 0.52% compared to ¥3,355,078,356.99 in 2018[68] - The company reported a total revenue of 3,219.5 million yuan for the period, which fell short of the forecasted 4,000 million yuan[153] Profitability and Margins - The gross profit margin for the year was 35%, indicating a stable profitability despite market fluctuations[16] - The company's gross profit margin in the chemical industry was 13.97%, down by 0.53% from the previous year[73] - The basic earnings per share for 2019 was ¥0.07, down 41.67% from ¥0.12 in the previous year[24] - The diluted earnings per share also stood at ¥0.07, a decrease of 41.67% compared to the previous year[24] - The weighted average return on equity was 2.08%, down from 4.22% in the previous year[24] Cash Flow and Investments - The net cash flow from operating activities was ¥95,892,729.31, showing a remarkable increase of 198.75% from the previous year[24] - The net cash flow from operating activities increased by 198.75% to ¥95,892,729.31, primarily due to the recovery of agency business payments from the previous year[92] - The net cash flow from investing activities rose by 109.49% to ¥27,457,809.71, while there were no acquisition payments in the current period[68] - The net cash flow from financing activities decreased by 89.09% to ¥82,190,957.39, primarily due to reduced borrowings and increased repayments[68] - Cash and cash equivalents net increase was ¥201,298,570.53, a decrease of 45.04% compared to the previous year[92] Research and Development - The company plans to invest RMB 200 million in R&D for new product development in the upcoming year, focusing on advanced chemical products[16] - Research and development expenses amounted to ¥87,580,449.56, which is 2.62% of operating revenue, showing an increase from 2.44% in the previous year[91] - The company has received multiple recognitions as a high-tech enterprise and has over 66 independent intellectual property patents, enhancing its R&D capabilities[52] - The company is committed to increasing R&D investment and enhancing technological innovation to improve core competitiveness[62] Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share within three years[16] - Future guidance indicates expected revenue growth of 20% for 2020, driven by new product launches and market expansion efforts[16] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[16] - The company expanded its business scope by acquiring stakes in two subsidiaries, increasing its operational footprint[78] Product Development and Offerings - The company has successfully launched a new line of electronic chemicals, contributing to a 30% increase in sales in that segment[16] - The company focuses on the production, R&D, and sales of chemical reagents and has expanded into in vitro diagnostic reagents and gene sequencing services[40] - The company has developed a comprehensive service solution for clients, providing customized chemical reagents and diagnostic kits for various applications, including tumor marker detection and respiratory infection testing[41] - The company expanded its product offerings in molecular diagnostics, with significant growth in sales volume and new installations for specific growth factor detection kits[65] Risk Management - The company has identified key risks including macroeconomic downturns and technological development risks, which will be closely monitored[4] - The company faces risks from macroeconomic downturns, which could impact demand and profitability[123] - Safety production risks are a concern due to the hazardous nature of chemical products, necessitating stringent safety measures[125] - Environmental risks are heightened by stricter regulations, requiring the company to optimize production processes for sustainability[126] Corporate Governance and Compliance - The company did not distribute cash dividends for the years 2017, 2018, and 2019, with net profits of approximately CNY 92.27 million, CNY 70.58 million, and CNY 38.53 million respectively, resulting in a cash dividend payout ratio of 0.00% for each year[134][133][132] - The company has committed to avoiding competition with its actual controllers and has plans in place for the reconstruction of facilities that may be affected by local government planning[142] - The company has confirmed that its business will not compete with the operations of Xilong Chemical after the non-public issuance[149] - The company reported no significant litigation or arbitration matters during the reporting period[174] Industry Trends - The electronic chemical industry is expected to grow rapidly due to the increasing demand from downstream applications such as semiconductors and solar energy[121] - The chemical reagent market is shifting towards specialization and high-end products, driven by increased competition and foreign market entry[122] - The in vitro diagnostic reagent industry is entering a growth phase, with significant market potential remaining untapped compared to developed countries[122]

西陇科学股份有限公司 2020 年第一季度报告全文 西陇科学股份有限公司 2020 年第一季度报告 1 2020 年 04 月 西陇科学股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人杜修鸿及会计机构负责人(会计主 管人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------|------------------|--------------------------| | | 本报告期 | | ...

西陇科学股份有限公司 2019 年第三季度报告 2019 年 10 月 西陇科学股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人杜修鸿及会计机构负责人(会计主 管人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|---------------------------------------------------------------|--------------------------------------------|------ ...

西陇科学股份有限公司 2019 年半年度报告 2019 年 08 月 西陇科学股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人黄伟鹏、主管会计工作负责人杜修鸿及会计机构负责人(会计主 管人员)刘艳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第四节"经营情况讨论与分析"的"十、公司面临的风险和应对 措施"中描述了公司经营中可能存在的风险及应对的措施，敬请投资者关注相关 内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 西陇科学股份有限公司 2019 年半年度报告全文 目录 | --- | |--------------------------------------------------------------------------------------------------------------------------------- ...

西陇科学股份有限公司 2019 年第一季度报告全文 西陇科学股份有限公司 2019 年第一季度报告 2019 年 04 月 1 西陇科学股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人蔡博及会计机构负责人(会计主管 人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|--------------------------| | □ 是 √ 否 | 本报告期 | 上年同期 | 本报 ...